Back to top

gene-editing: Archive

Zacks Equity Research

Vertex (VRTX) Inks New Deal for CRISPR Gene-Editing Rights

Vertex (VRTX) collaboration with Arbor will support discovery & development of new treatment options for serious diseases using the latter's CRISPR technology.

VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change KYMRPositive Net Change

Zacks Equity Research

Editas (EDIT) Up More Than 70% in Past 3 Months: Here's Why

Editas' (EDIT) lead candidate, EDIT-101, which employs CRISPR gene editing to treat LCA10, holds potential. The company is also developing EDIT-301 for treating hematologic diseases.

BEAMPositive Net Change EDITPositive Net Change NTLAPositive Net Change CRSPPositive Net Change